This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Mitsubishi Tanabe Pharma Corporation
Drug Names(s): TA-6666
Description: TA-6666 is a dipeptidyl peptidase IV (DPP-IV) inhibitor. Through DPP IV enzyme inhibition, TA-6666maintains a level of endogeneous GLP-1 and leads to theacceleration of the secretion of insulin accompanying the rise inblood glucose level after meal intake, but it does not influenceinsulin secretion under fasting conditions.
Deal Structure: TA-6666 was developed by Tanabe.
In October 2007, Mitsubishi Tanabe Pharma Corporation was formed by the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation.
Additional information available to subscribers only: